



OPEN ACCESS

EDITED AND REVIEWED BY
Richard D. Boyle,
National Aeronautics and Space
Administration (NASA), United States

*CORRESPONDENCE
Maria G. Trivella,
✉ mariagiovanna.trivella@cnr.it

SPECIALTY SECTION
This article was submitted to
Environmental, Aviation
and Space Physiology,
a section of the journal
Frontiers in Physiology

RECEIVED 06 March 2023
ACCEPTED 08 March 2023
PUBLISHED 14 March 2023

CITATION
Trivella MG, Capobianco E and L'Abbate A
(2023), Editorial: Physiology in extreme
conditions: Adaptations and unexpected
reactions, Volume II.
Front. Physiol. 14:1181010.
doi: 10.3389/fphys.2023.1181010

COPYRIGHT
© 2023 Trivella, Capobianco and
L'Abbate. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or
reproduction in other forums is
permitted, provided the original author(s)
and the copyright owner(s) are credited
and that the original publication in this
journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Editorial: Physiology in extreme conditions: Adaptations and unexpected reactions, Volume II

Maria G. Trivella^{1*}, Enrico Capobianco² and Antonio L'Abbate³

¹Consiglio Nazionale delle Ricerche, Institute of Clinical Physiology, Pisa, Italy, ²The Jackson Laboratory, Computational Science, Farmington, CT, United States, ³Scuola Superiore Sant'Anna, Pisa, Italy

KEYWORDS

extreme environments, adaptation, underwater, space, altitude, confined environment, heart failure

Editorial on the Research Topic

Physiology in extreme conditions: Adaptations and unexpected reactions, Volume II

This Research Topic is an extension of our previous Physiology in extreme conditions (Vol. I), and a first general observation is that Vol. II confirms some of the conclusion reported in Vol. I with reference to two major identified needs:

- Enhancing our knowledge and understanding of individual reactions and adaptation mechanisms observed in specific and unusually severe environmental conditions;
- Increasing both the availability and the accessibility of data generated in extreme conditions, with the possibility to infer more about both variability and protective capacities among individuals.

A few case studies were presented in the articles of Vol. II covering preclinical models (Desruelle et al.; Siamwala et al.; Bao et al.; Niu et al.) and clinical work, with the latter involving healthy individuals observed in non-physiological environments (Shved et al.) and severely ill children subjected to specific pharmacological treatments (Adorisio et al.) commonly used in adult patients for many years (Packer et al., 1996; Agarwal and Venugopalan, 2001).

Then, our curated Research Topic of contributed work includes animal models whose reference scenarios are states of adaptation to unfavourable environments. For instance, the association between a Cecal compound and metabolomic signatures is relevant, which emphasizes individual differences by analysing metabolic compound effects combined with host/microbial communities in diver rats (Desruelle et al., in review).

A first important remark is that well-conducted preclinical models help interpret complex phenomena affecting human beings, like those occurring in extreme conditions. It is worth mentioning that the expectation here is to increase our ability to understand the correct behaviours that may limit or even avoid potentially damaging impacts on health.

A second important remark is that a few key health warnings are identified in the published studies. They include: A) Avoiding decompression illness, B) Stressing the role of antioxidant protection in adapting to height, C) Understanding the effects of space on the structural physiological mechanisms and their angiogenesis- and/or osteogenesis-induced modifications, together with the genetic factors (Siamwala et al.).




FIGURE 1

Healthy vs. diseased heart: beyond the therapeutic frontiers, VAD as transient therapeutic tool for heart recovery and/or possible gene therapy. Original author and copyright owner: MG Trivella.

In particular, the decompression illness is a well-known threat to the safety of submariners, noting that the maximum depth at which a safe escape is possible is unknown and that targeted studies of maximum safe escape at different depth were carried out in rabbits' models (Bao et al.).

Significant results emerge from the study on *Nanorana parkeri* (common names: High Himalaya frog) (Niu et al.) that demonstrated differentiability between high- and low-altitude populations regarding factors such as robust hematologic parameters, less oxidative damage, and stronger antioxidant protection, all contributing to increased survival in high-altitude environments.

A third remark is for clinical trials, which require additional analysis.

The isolation in a confined environment of a small group of "healthy" subjects of mixed gender, defined as "experiment with short-term isolation" (Shved et al.) induces in general adaptation to the stressful environment with different behaviours of extrovert versus introvert subjects, pointing out individual characteristics. Whether living in space could represent a future possibility or not, the basic problem that emerges is knowing the adaptation mechanisms given the induced changes and what countermeasures are appropriate to avoid pathological conditions. In Vol I°, a study conducted by Demontis et al. (2017) on the human pathophysiological adaptations to space indicated the need to select well-trained healthy individuals carefully. In Vol II°, an additional factor became useful for evaluating astronauts' skillset, one typically part of the psychological profile (Shved et al.).

Other considerations are needed for the cardiology work on small decompensated paediatric patients (Adorisio et al.). Here the high frequency physiologically present in children (Fleming et al., 2011), also accentuated by the pathological state, is shown to be significantly reduced after pharmacological treatment. This ultimately leads to a reduction of disease severity and/or healing, in line with the beneficial effects of vagus compared to the prevalence of sympathetic in cardiovascular balance (Capilupi et al., 2020). Since the improvement of the left ventricular ejection fraction was enhanced by a major reduction in heart rate

(HR), it appears evident that HR could be used as a clinical marker during the treatment of heart failure in children. This evidence could mean a main change and an alternative route in therapy because reducing the need for ventricular assist device implantation as an intermediate procedure before heart transplantation (Di Molfetta et al., 2016; Villa and Morales, 2017).

In review, it is important to mention that heart failure of different degrees and the possible health recovery involve understanding adaptation and homeostasis recovery mechanisms. The literature offers examples (i.e., ventricular assistance systems (VAD) solutions as per Simon et al., 2005; Dandel and Hetzer, 2015; Nesta et al., 2021) (Figure 1). Adorisio et al. show that different treatments could help in understanding adaptation. Also, future gene therapies could add valuable information on this Research Topic (Lim, 2019; Giacca, 2020; Kaur and Zangi, 2020).

Author contributions

MGT drafted the editorial. EC edited the text and reviewed the editorial. AL'A reviewed the editorial.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

- Agarwal, A. K., and Venugopalan, P. (2001). Beneficial effect of carvedilol on heart rate response to exercise in digitalised patients with heart failure in atrial fibrillation due to idiopathic dilated cardiomyopathy. *Eur. J. Heart Fail* 3, 437. doi:10.1016/s1388-9842(01)00130-1
- Dandel, M., and Hetzer, R. (2015). Myocardial recovery during mechanical circulatory support: Long-term outcome and elective ventricular assist device implantation to promote recovery as a treatment goal. *Heart Lung vessel*. 7 (4), 289–296. PMID: 26811834 PMID: PMC4712031.
- Demontis, G. C., Germani, M. M., Caiani, E. G., Barravecchia, I., Passino, C., and Angeloni, D. (2017). Human pathophysiological adaptations to the space environment. *Front. Physiol.* 8, 547. doi:10.3389/fphys.2017.00547
- Di Molfetta, A., Gandolfo, F., Filippelli, S., Perri, G., Di Chiara, L., Iacobelli, R., et al. (2016). The use of berlin heart excor VAD in children less than 10 kg: A single center experience. *Front. Physiol.* 7, 614. doi:10.3389/fphys.2016.00614
- Fleming, S., Thompson, M., Stevens, R., Heneghan, C., Plüddemann, A., Maconochie, I., et al. (2011). Normal ranges of heart rate and respiratory rate in children from birth to 18 years of age: A systematic review of observational studies. *Lancet* 377 (9770), 1011–1018. doi:10.1016/S0140-6736(10)62226-X
- Giacca, M. (2020). Cardiac regeneration after myocardial infarction: An approachable goal. *Curr. Cardiol. Rep.* 22 (10), 122. doi:10.1007/s11886-020-01361-7
- Kaur, K., and Zangi, L. (2020) Modified mRNA as a therapeutic tool for the heart. *Rev. Cardiovasc Drugs Ther.* 34(6), 871–880. doi:10.1007/s10557-020-07051-4
- Lim, G. B. (2019). MicroRNA-directed cardiac repair after myocardial infarction in pigs. *Nat. Rev. Cardio* 16, 454–455. doi:10.1038/s41569-019-0216-z
- Capilupi, M. J., Kerath, S. M., and Becker, L. B. (2020) Vagus nerve stimulation and the cardiovascular system. *Cold Spring Harb. Perspect. Med.* 10, a034173. doi:10.1101/cshperspect.a034173
- Nesta, M., Cammertoni, F., Bruno, P., and Massetti, M. (2021). Implantable ventricular assistance systems (VAD) as a bridge to transplant or as 'destination therapy'. *J. Suppl.* 23, E99–E102. doi:10.1093/eurheartj/soab101
- Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., et al. (1996). The effect of carvedilol on morbidity and mortality in patients failure U.S. Carvedilol heart failure study group. *N. Engl. J. Med.* 334, 1349. doi:10.1056/NEJM199605233342101
- Simon, M. A., Kormos, R. L., Murali, S., Nair, P., Heffernan, M., Gorcsan, J., et al. (2005) Myocardial recovery using ventricular assist devices prevalence, clinical characteristics, and outcomes. *Circulation* 112:132 doi:10.1161/CIRCULATIONAHA.104.524124
- Villa, C. R., and Morales, D. L. S. (2017). The total artificial heart in end-stage congenital heart disease. *Front. Physiol.* 8, 131. doi:10.3389/fphys.2017.00131